Welcome to Sequence Card of Peptide
Details of CPPsite entry with Sequence YGRKKRRQRRR |
| Primary information | |
|---|---|
| PEPTIDE SEQUENCE | YGRKKRRQRRR |
| CPPsite ID | 2010, 2089, 2090, 2091, 2094, 2121, 2129, 2221, 2291, 2311, 2317, 2324, 2347, 2413, 2441, 2448, 2503, 2504, 2506, 2543, 2544, 2551, 2552, 2563, 2596, 2679, 2905, 1494, |
| PEPTIDE NAME | Tat-AIE dots, 6His-TAT-Ainp1, 6His-TAT-GFP, 6xHis-TAT-SOD, Tat-GFP, TAT, TAT-gelonin, EGFP-TAT, P42-TAT, TAT(47-57), TAT(47-57), HIV-TAT (47-57), TAT-ELPBC, Tat, PNIPAM-FL-TAT Peptide, SP-TatCherry, TAT-BID, TAT-lyophiliosomes, Tat, CF-TAT-substrate, Ac-TAT-substrate, ST1-104, ST9-104, TAT-EGFP, fTat, Tat, TAT (47-57), Tat (47-57) |
| CHIRALITY | L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, Modified, L, L, L, L, L, L, L, L, L |
| LINEAR/CYCLIC | Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear |
| SOURCE | Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Synthetic, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived, Protein derived |
| CATEGORY | Amphipathic, Cationic, Cationic, Cationic, NA, NA, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Amphipathic, Cationic, Cationic, Cationic, NA, NA, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic |
| SUB CELLULAR LOCALIZATION | Cytoplasm, Nucleus, Nucleus, Cytoplasm, NA, Free, NA, Cytoplasm and Nucleus, Cytoplasm and Nucelus, NA, Cytoplasm, Nucleus, NA, Cytoplasm, Lysosomes and some in Cytoplasm, Cytoplasm, NA, NA, Cytoplasm, Cytosol, Cytosol, NA, NA, Cytoplasm and Nucleus, NA, Cytoplasm, Cytoplasm, Cytosol |
| N-TERMINAL MODIFICATION | Free, Free, Free, Free, Free, Free, Free, Conjugated with EGFP, Free, Free, Biotinylation, Free, Conjugation with ELPBC, Free, Conjugated with PNIPAM-FL molecule, Coupled to signal peptide, Conjugation with 6-histidine tag, Conjugated with lyophilisome via cysteine linker, Free, Conjugation with 5(6)-carboxyfluorescein N-hydroxysuccinimidyl ester, Acetylation, Free, Free, Conjugation with EGFP, Conjugation with 5(6)-Carboxyfluorescein, NA, Free, Conjugation with Texas red |
| C-TERMINAL MODIFICATION | Free, Free, Free, Free, Free, NA, Free, Free, Free, Free, Amidation, Amidation, Free, Amidation, Free, Conjugation with mCherry, Conjugation with BID-3xHA, Free, Conjugation with Avidin-FITC, Conjugation with substrate, Conjugation with substrate, Conjugation with CBD3 peptide of CRMP2, Conjugation with reverse sequence of CBD3 peptide of CRMP2, Free, Free, NA, Free, Free |
| CHEMICAL MODIFICATION | NA, Histidine tagged, Histidine tagged, Histidine tagged, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, Biotinylation, NA, NA, NA, NA, NA, NA, NA, NA, NA |
| UPTAKE EFFICIENCY | NA, NA, NA, Cells with treatments of FMSN-TAT- SOD give a very strong SOD signal., Unable to penetrate PC-3 cells at 5 mM concentartion, High, Strong fluorescence signal was observed inside the cells incubated with TAT-gelonin, indicating rapid and efficient transduction of TAT-gelonin mediated by TAT, Showed increased uptake efficiency, Higher uptake efficiency, Lower uptake efficiency, Lower than penetratin and R6W4, NA, Higher uptake, NA, No difference in the intracellular distribution of PNIPAM and PNIPAM-TAT particles, Low, Dose dependent uptake, Higher uptake efficiency, KST peptide demonstrated profound penetration into the cells of both lines with the same efficiency as the full-length chap- erone tagged with Alexa489, NA, NA, Lower uptake efficiency, Lower uptake efficiency, Transported EGFP into the Cytoplasm in great amount and even into the nucleus partly., NA, NA, NA, Unknown |
| PROPOSED UPTAKE MECHANISM | NA, NA, NA, Endocytic pathway, Endocytic pathway, NA, Fluid phase pinocytosis, NA, NA, NA, Endocytic pathway, NA, NA, Clathrin dependent uptake, NA, NA, NA, Phagocytosis or macropinocytosis, NA, Endosomal uptake, Endosomal uptake, NA, NA, NA, NA, NA, Endocytic pathways, Condition dependent (not determined in this paper) |
| INVITRO/INVIVO | In vitro and in vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro and in vivo, In vitro, In vitro and in vivo, In vitro and in vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro and in vivo, In vitro and in vivo, In vitro and in vivo, In vitro, In vitro and in vivo, In vitro, In vitro |
| CELL LINE | MCF-7 and C6 cells, HeLa, MCF-7, and Hep3B cells, HeLa, MCF-7, and Hep3B cells, HeLa, PC-3 cells, KB cells, LS174T and HCT116, MDCK and 293 HEK, Mouse macrophage-like cell line J774 A.1, HeLa, CT26 mouse colon cancer cells, HeLa and Hep3B cells, CHO-K1 (WT) and xylose transferase- or GAG-deficient CHO-pgsA745 cells (GAGneg), HeLa, COS-7, NIH-3T3, Jurkat, NB-4, Kasumi-1, Leishmania tarentolae cell line, HeLa, HeLa, CHO and Jurkat cells, A549, H1299, A549 and CHO-K1, PC3, LNCaP, A549, and HeLa, HeLa, OVCAR-3, Caco-2 and SKOV-3 cells, K-562, A-431, T98G, and 3T3 and 3T3-SV-41, HeLa Cells, HeLa Cells, Brain lysates prepared from embryonic day 19 rats, Brain lysates prepared from embryonic day 19 rats, The mouse macrophage J774 A.1 cells, Human dermal fibroblasts, H9C2 cells, NIH 3T3 cells, Huh7 and A549, PC12 cells, HeLa or TM12 cells |
| In VIVO MODEL | Male SCID mice, NA, NA, NA, NA, NA, C57BL/6 mice, NA, C57BL/6 mice, R6/2 transgenic and wild-type mice, Male Balb/c mice, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, Female Sprague Dawley rats, Female Sprague Dawley rats, Zebrafish, NA, BALB/c mice, NA, NA |
| CARGO | TPETPAFN and TPAFN, Peptide (Ainp1), Protein (eGFP), Protein (Cu,Zn-superoxide dismutase), Protein (eGFP), Small molecule drug (Doxorubicin and Paclitaxel), Protein (gelonin), Protein (eGFP), P42-TAT incorporated in a water-in-oil microemulsion, Peptide (Mitochondrial Target Domain of NOXA), Biotin-gly4, Protein (ATTO488-BSA, ?-galactosidase), Peptide (BH3 peptide drug and ELPBC), Fluorophore [5(6)-carboxyfluorescein], Nanoparticle [poly(N-isopropylacrylamide) (PNIPAM) microgel particles], Fluorophore (mCherry), Protein (BID), Nanoparticle (Lyophiliosomes and FITC labelled), Protein (Avidin-FITC), Fluorophore (Fluorescein), substrate, Fluorophore (Fluorescein), substrate, Peptide [Ca2+ channel binding domain 9CBD3)], Peptide [Ca2+ channel binding domain 9CBD3)], Protein (eGFP), Fluorophore (Carboxyflouresein), Nucleic acid (siRNA), Nanoparticle (Quantum dots), Fluorophore (Texas Red) |
| PMID | 23359649, 23454269, 23454269, 23289802, 23521800, 23792465, 25204286, 24746937, 25091984, 24416126, 25112713, 24275947, 24611762, 24870379, 25170605, 24928321, 25326334, 25369131, 25387797, 23621550, 23621550, 23106100, 23106100, 24746937, 24657280, 22452378, 25570933, 12417587 |
| PATENT | Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown |
| Tertiary Structure (Technique) | 2010 (PEPstrMOD), 2089 (PEPstrMOD), 2090 (PEPstrMOD), 2091 (PEPstrMOD), 2094 (PEPstrMOD), 2121 (PEPstrMOD), 2129 (PEPstrMOD), 2221 (PEPstrMOD), 2291 (PEPstrMOD), 2311 (PEPstrMOD), 2317 (PEPstrMOD), 2324 (PEPstrMOD), 2347 (PEPstrMOD), 2413 (PEPstrMOD), 2441 (PEPstrMOD), 2448 (PEPstrMOD), 2503 (PEPstrMOD), 2504 (PEPstrMOD), 2506 (PEPstrMOD), 2543 (PEPstrMOD), 2544 (PEPstrMOD), 2551 (PEPstrMOD), 2552 (PEPstrMOD), 2563 (PEPstrMOD), 2596 (PEPstrMOD), 2679 (PEPstrMOD), 2905 (PEPstrMOD), 1494 (PEPstrMOD), |